The Board's experience and skills are complimentary and diverse
bringing together commercial, scientific, medical and legal expertise.
Jitto Arulampalam who is the current Chairman of Lanka Graphite (Australian public company) is a Melbourne based businessman with over 20 years of extensive experience in corporate restructuring, capital raising, listing and running of public companies on the ASX. Having started his career in Accounting, Jitto spent more than 8 years with Westpac Banking Corporation in several key operational and strategic Banking roles before joining boards of Public companies. In 2004 Jitto was head hunted by Newsnet Ltd as its CEO to assist in the restructuring of the company and to position it for an IPO. Since this appointment he was responsible for guiding the company through a successful restructure and positioned Newsnet as a leading innovator in the messaging/telco space to be recognised by the 2006 Australian Financial Review MIS Magazine as one of the "Top 25 global rising stars". In May 2010 Jitto co‐founded ASX listed postash mining and exploration company Fortis Mining Ltd (ASX: FMJ). As the Executive Chairman, Jitto was instrumental in the company's acquisition of world class potash assets in Kazakhstan, a monumental deal which ultimately led to the company being awarded "IPO of the Year 2011". Jitto was also previously the Chairman of ASX listed companies Great Western Exploration Ltd (ASX: GTE) and Medicvision Limited (ASX: MVH). Jitto is a member of many professionals bodies including the Australian Institute of Company Directors.
Dr. Chang is the Chairman of Medigen Biotechnology Corporation (Medigen), with an MD degree from National Taiwan University College of Medicine and a Ph.D. degree in Laser Medicine from the University College London of London University, UK.
Dr. Chang is a Urological surgeon by training, and was formerly a professor in Urology, and the chairman of Faculty of Medicine at Tzu-Chi Medical College, Taiwan. He changed the career track to biotech business in 2000, and became the CEO and Chairman of both Medigen and Medigen Vaccine Biologics Corp. (MVC).
Medigen is a publicly listed company in Taiwan, focusing on monoclonal antibody discovery, cancer drug developments, and molecular diagnostic kits/devices manufacturing and marketing. MVC on the other hand is a subsidiary of Medigen, devoted to cellbased technology for vaccine production. MVC is constructing a PIC/s certified vaccine manufacturing plant for pandemic/seasonal flu vaccines and EV71 enterovirus vaccines in Taiwan. The state-of-the-art cell-based vaccine production plant is planned to go through EU's PIC/s GMP inspection and start operation in 2016.
Mr Cheng is the Group Chief Officer Operation (COO) of TBG Diagnostics Limited (TDL). Mr. Cheng joined Medigen Biotechnology Corp in 2004 and initiated the molecular diagnostics business in 2006 by the acquisition of Texas Biogene, Inc. (TBG), a biotech company based in Dallas, USA, specializing in the development of tissue typing products that are marketed under the TBG brand. Mr. Cheng also spearheaded the acquisition of Haoyuan in Shanghai, China, in 2007, and its divestiture to Perkin Elmer in 2012 when Haoyuan became the leading local brand in the NAT blood screening market in China. Armed with the knowledge and experience in the Chinese market, TBG aims to become one of the leading molecular diagnostics brands in China within 5 years. As part of the strategy to achieve that goal, TBG was re-listed on ASX through a reverse merger with Progen Pharmaceutical (PGL) in February 2016. Currently, Mr. Cheng serves as a director of both Medigen and TDL.
Ms Emily Lee, who is the current Managing Director of ASX listed company Lanka Graphite Limited (ASX:LGR), is a Melbourne based businesswoman with a substantial track record of success in cross border transactions within the corporate and government sectors in Australia and Asia. Ms. Lee has extensive experience in corporate restructuring, capital raising, listing and managing of public companies on the ASX.
Ms Lee serves as Managing Director of Mercer Capital, a boutique private equity firm based in Melbourne. In May 2013, she was instrumental in leading a successful underwriting and capital raising exceeding $5 million for Progen Pharmaceuticals Limited (ASX:PGL). In August 2015, she successfully raised $3.8 million for Lanka Graphite Limited following the successful merger of Viculus Limited and Euro Petroleum.
Mercer Capital has been the lead strategic Corporate Advisor for Progen on managing and facilitating the corporate restructuring of the company and acquisition of Texas BioGene (TBG).
Ms Lee previously held position as non-executive chairman for ASX listed company Australian Natural Proteins Limited (ASX:AYB) and is a member of the Australian Institute of Directors (MAICD)..
Mr. Edward Chang is the Director of Finance Department at Eternal Materials Co., Ltd., a leading chemical material provider based in Taiwan. Edward holds a master's degree in Business Administration from the Schulich School of Business at York University in Canada.
Prior to joining the firm, Edward worked at Motech Industries, Inc., a leading photovoltaic (PV) cell provider based in Taiwan, as Manager of Treasury and Risk Management Department.
Eternal Materials Co., Ltd.("Eternal" or the "Company"), formerly Eternal Chemical Co., Ltd., was founded in 1964 as a coating resins provider. Eternal has since then diversified its product portfolio making use of synthetic resins, precision coating technology and specialty chemicals. The Company currently consists of three business groups focusing on the manufacture and sale of synthetic resins, electronic chemical materials and specialty chemicals. Eternal is the largest supplier of dry film photoresist in the world, as well as one of global top suppliers of UV curing materials and a leading supplier of synthetic resins in Asia.
The Company is headquartered in Kaohsuing, Taiwan, with main manufacturing facilities based in Taiwan, Mainland China, and the United States. Eternal is a publicly listed company on the Taiwan Stock Exchange under ticker number 1717.